Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Researchers Warn Against Targeting Only One Viral Gene for SARS-CoV-2 Detection by RT-PCR Due to Mutation in N Gene

By LabMedica International staff writers
Posted on 31 Aug 2020
Researchers have warned against targeting only one viral gene when carrying out reverse transcriptase-polymerase chain reaction (RT-PCR) testing for the SARS-CoV-2 virus, according to a report by News Medical.

A team of researchers at the Chan Zuckerberg Biohub (San Francisco, CA, USA) carried out a study to demonstrate that a mutation had occurred in the N gene of the SARS-CoV-2 virus that impaired the annealing of a commonly used RT-PCR primer. More...


Testing for SARS-CoV-2 generally involves using RT-PCR to test for the viral genome in respiratory samples and is performed using primer pairs that target more than one viral gene. The protocol involves assays that target the N gene and the E gene in SAR-VoV-2, and other groups commonly use these assays. However, the WHO has recommended that “in areas where the COVID-19 virus is widely spread, a simpler algorithm might be adopted in which, for example, screening by RT-PCR of a single discriminatory target is considered sufficient.”

In July, the researchers had identified clustering of 35 samples that showed poor assay performance for the N gene, but not the E gene. In order to identify the potential reasons for this, the team carried out a study that identified a nucleotide change in an N gene primer sequence that disrupted annealing and amplification, thus reducing diagnostic sensitivity. Based on their findings, the researchers have suggested the routine use of at least two targets when testing for SARS-CoV-2 using RT-PCR, even in areas where transmission rates are high, according to the News Medical report.

According to the researchers, their findings suggest that even in areas where community spread of SARS-CoV-2 is high, mutations can occur that impair recognition of RT-PCR primers and reduce diagnostic sensitivity, leading to under-diagnosis if laboratories used only one target for SARS-CoV-2 detection.

Related Links:
Chan Zuckerberg Biohub


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.